Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand - Wikidata - awgldk - TriplyDB

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

http://www.wikidata.org/entity/Q35468295

about

Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET)Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.Imaging in Dementia With Lewy Bodies: An Overview.Rapidly progressive diffuse Lewy body disease.Unveiling molecular events in the brain by noninvasive imaging.Cerebrospinal fluid biomarkers for dementia with lewy bodies.UPDATE ON DEMENTIA WITH LEWY BODIES.Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study.Emerging biomarkers in cognition.Dementia with Lewy bodies: clinical characteristics and diagnostic criteria.Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment CT-based attenuation correction in I-123-ioflupane SPECT Functional imaging in Parkinson's disease and dementia with Lewy bodies.Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies.Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease Importance of (123)I-ioflupane SPECT and Myocardial MIBG Scintigraphy to Determine the Candidate of Deep Brain Stimulation for Parkinson's Disease Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.SPECT imaging in dementia.Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.The cingulate island sign within early Alzheimer's disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer's disease from dementia with Lewy bodies Inflaming the diseased brain: a role for tainted melanins.The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging.Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.Imaging cognitive and behavioral symptoms in Parkinson's disease.Biomarkers in dementia with Lewy bodies: a review.The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.Dopaminergic imaging: clinical utility now and in the future.Nuclear medicine imaging in dementia: a practical overview for hospitalists.Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer's Disease - An Unexpected Finding?Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer's disease using brain perfusion SPECT.Lewy Body Dementia: The Under-Recognized but Common FOE.(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A compa Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.

P2860

Q24186395-1A18F5E8-D672-4CE3-A94E-123BF05687C3 Q24201437-4BADA3E0-C801-4B72-93C5-1BF4EBC75E67 Q24805277-AFBCACB8-EF2C-42C0-B7E4-BB44F45690CF Q30480599-E85BB300-BD76-4510-BFF0-0404E4E4A30E Q31047131-329F2527-D18B-4BC1-99D3-F20F6FDA344E Q31120307-0B0B4535-677A-4290-AF86-7FB22FDBDC8C Q33870090-8DC81003-2FBF-4D2A-8ACE-77BA69C36D54 Q34046040-D4375EC5-3A6C-4CFB-8B0C-CD7976BB4BD1 Q34248241-431A5BFC-CBA1-461F-87BC-B19ED93B7839 Q34450376-AD67E6BE-3384-43DE-A990-2FBF4FAA4618 Q34554452-F1A0C881-4BDB-4DCE-81C8-C5DB0CA7E770 Q34576144-E4BF8B57-09DA-46DE-9893-5AE55AA0C107 Q35008258-FE51E66D-12A8-45D6-8597-112631260881 Q35029466-127FB6DC-7482-4908-BF54-3E11B8900383 Q35120662-68A427B8-27D7-492C-B28D-DEA15E525CBA Q35287222-355DA6F9-2342-4EB5-A059-A8B4D0D239D0 Q35863417-381490EA-EA36-4092-A94B-544EF5526F87 Q36226642-D393ED8B-CF47-4F4E-A57B-0E6D4D5A5CC2 Q36226812-698DDEF6-D2A7-4F0B-B4CC-A196D3237B13 Q36373719-DB9FFADF-D0E4-4FDD-B88A-44A832D549BC Q36685622-817A0961-F4E8-4FEF-8E01-D8666ACEAF59 Q36724965-5BEC3304-450C-4AF8-9218-81338559517F Q37150640-73C06D19-A687-4BCD-B0FC-7CE7F1DA6AFD Q37228453-BD10B889-6A75-474C-A2F9-A52FECBD50A8 Q37250257-06FAA402-D083-40D8-BAAE-E29961E86419 Q37419866-D05D7145-4A96-4AE0-97DD-0C6CF3BE2EE7 Q37605294-3BF53712-E92C-4433-9032-AC2CE56C0A28 Q37610726-E6B14198-5924-4912-9B68-B4891116D5F5 Q37810993-4810B985-56D3-4195-BEC5-E3D50BA9CB05 Q37896548-708B9CE3-CA4C-4AC7-BE73-5EFD821C405C Q37910636-4A244BFC-DD05-41A2-9641-AAD2891D59F0 Q37917854-307DB6FC-9F92-46EF-BFF6-09497C9F391E Q37924516-D71C19DD-E32B-4EB3-AE59-DBC660582053 Q38006466-1083E8E2-AA8B-411F-954D-E0AA3E101647 Q38762171-7837200E-1404-43F4-8663-C2860CE37DB6 Q38969273-E5DF5732-345A-4519-AE07-8DFA1C3B06AC Q39615532-9B2E58D2-15BF-492D-B0C0-E565C03CB9B3 Q41635671-AD028B8D-8FF1-4A60-A18F-594757FDBE69 Q43164212-80150559-31C6-4013-B90A-E805ED79E0E2 Q44790322-831CB5A2-8A48-4A1C-86D3-7FF95B665DA4

P2860

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

http://www.wikidata.org/entity/Q35468295

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Differentiation of dementia wi ...... opaminergic presynaptic ligand

@ast

Differentiation of dementia wi ...... opaminergic presynaptic ligand

@en

type

label

Differentiation of dementia wi ...... opaminergic presynaptic ligand

@ast

Differentiation of dementia wi ...... opaminergic presynaptic ligand

@en

prefLabel

Differentiation of dementia wi ...... opaminergic presynaptic ligand

@ast

Differentiation of dementia wi ...... opaminergic presynaptic ligand

@en

P1433

Q35468295-9515D658-418F-438B-90FA-8C2621BDF854

P1476

Q35468295-31E9D734-3607-461C-97DE-8953846F9842

P2093

Q35468295-49926219-3D63-447B-8611-1F3512540EC1

Q35468295-6EB35DA8-3E91-4D86-92D5-9B3F4E0932A8

Q35468295-9AED38F1-109D-49AC-BE3A-10A0B9E0B8D7

Q35468295-9BCC68DF-9EF9-4859-9635-AD8AE48F562B

Q35468295-A3155303-DCDF-4C2D-B7AC-10722C3FA72B

Q35468295-B5F47C6B-927C-4281-9CD7-8DAC863880F8

Q35468295-BFD192B6-D4FB-4344-8DF8-314CB46D6805

Q35468295-CA1307F5-74C4-4C73-B454-2F55E81ED5F4

Q35468295-E4B47E2D-FC07-4D77-896F-E51726E4465D

Q35468295-F7F08F22-5CEE-485C-BA5A-FB2590736070

P2860

Q35468295-00E1B863-9F02-49FB-AE02-FF2017048D0F

Q35468295-10056EBF-2A63-418B-A66B-D8B98CD6364C

Q35468295-13CE432F-0EBA-49D7-A342-303ACE342656

Q35468295-1BB76B81-0375-42E7-8785-F4A2B9EAC6F4

Q35468295-1D8FAF96-8E80-4A00-879C-59D4499AF037

Q35468295-1D90064C-488D-40B8-A31E-8B2A9333386E

Q35468295-268A022F-AF58-4CDA-9C59-85FC1ED53548

Q35468295-396B840C-F149-4111-80A7-BD0C1DB4AA5F

Q35468295-3CC46AA3-97AB-43E4-9B23-33A6D80443A3

Q35468295-57006D02-C3E5-470A-A3E7-316FBC544DEA

P304

Q35468295-F3340232-EEDB-4739-AD84-41EA86DDEE19

P31

Q35468295-D32082C8-6EC4-48B7-B4CB-C241A72BEF69

P356

Q35468295-B61E028A-1CDE-400A-8550-546C828FCBF7

P407

Q35468295-9B5F9E4D-E792-41BB-A215-0F7F12771A7A

P433

Q35468295-676F31E8-F017-4766-81BD-22863F8E2F0A

P478

Q35468295-F1F6823C-F550-4CC1-BFFA-BD055AB30A66

P577

Q35468295-9F89D000-A517-44D2-ACE7-FBCCC88F6658

P5875

Q35468295-89BB0436-B6D8-44E6-A7FD-434B79890FEF

P698

Q35468295-86C06FBD-9EBD-40EF-BBA3-BA002C2B1589

P921

Q35468295-18C367E4-63CA-415C-83AC-739AD56E14E7

Q35468295-561A289B-119C-4F26-8572-373C2645F8EE

Q35468295-FD86B366-F685-4C62-A7D2-1391ED075301

P932

Q35468295-90D502A4-0CC4-4B8C-B742-1C56F5F6A465

P356

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Differentiation of dementia wi ...... opaminergic presynaptic ligand

@en

P2093

Costa DC

http://www.w3.org/2001/XMLSchema#string

Gacinovic S

http://www.w3.org/2001/XMLSchema#string

Ince P

http://www.w3.org/2001/XMLSchema#string

Katona CL

http://www.w3.org/2001/XMLSchema#string

Livingston G

http://www.w3.org/2001/XMLSchema#string

McKeith IG

http://www.w3.org/2001/XMLSchema#string

Shaw K

http://www.w3.org/2001/XMLSchema#string

Stevens T

http://www.w3.org/2001/XMLSchema#string

Walker RW

http://www.w3.org/2001/XMLSchema#string

Walker Z

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Parkinsonism: onset, progression and mortality

Core assessment program for intracerebral transplantations (CAPIT)

SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.

Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample.

Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

P304

134-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.73.2.134

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11257139

http://www.w3.org/2001/XMLSchema#string

P698

12122169

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1737968

http://www.w3.org/2001/XMLSchema#string